CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CIDP drug aims to keep nerve damage at bay
Disease control Recruiting nowThis study tests an investigational drug called IMVT-1402 in adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system attacks the nerves. The goal is to see if the drug can prevent relapses and improve strength and function. About …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated May 26, 2026 03:31 UTC
-
New hope for nerve disease patients: blood-filtering therapy tested
Disease control Recruiting nowThis study looks at a treatment called immunoadsorption (IA) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. About 140 adults who did not get better with standard treatments will be switched to IA and fo…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Sponsor: University of Ulm • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New CIDP drug aims to keep nerve damage at bay
Disease control Recruiting nowThis study tests an experimental drug called DNTH103 (claseprubart) against a placebo in 256 adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The goal is to see if the drug can delay or prevent relapses an…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New study seeks better dose of immune therapy for nerve disease
Disease control Recruiting nowThis study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher o…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New shot may replace monthly IV infusions for nerve disorder
Disease control Recruiting nowThis study tests a new drug called riliprubart against standard IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 160 adults who already use IVIg will receive either riliprubart or I…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Experimental CAR T-Cell therapy takes on multiple sclerosis and other nerve diseases
Disease control Recruiting nowThis early-stage study is testing a new treatment called KITE-363 for people with autoimmune neurologic diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy that have not responded to standard therapies. KITE-363 uses a patien…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New drug could replace standard IV therapy for nerve disorder
Disease control Recruiting nowThis study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and numbness. About 218 adults who have previously responded to IVIg will re…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New CIDP drug trial offers hope for nerve damage relief
Disease control Recruiting nowThis study tests a new drug called empasiprubart for adults with CIDP, a condition that causes nerve damage and weakness. About 160 people will receive either the drug or a placebo for 6 months, then everyone gets the drug for 2 more years. The goal is to see if it improves disab…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Could electrical shocks help weak muscles? new study hopes to find out
Symptom relief Recruiting nowThis study is testing whether whole-body electrical muscle stimulation (WB-EMS) can help adults with neuromuscular diseases like ALS, muscular dystrophy, and myasthenia gravis exercise safely. Because these conditions make normal exercise difficult, WB-EMS uses electrical pulses …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: NA • Sponsor: University of Missouri-Columbia • Aim: Symptom relief
Last updated May 26, 2026 03:30 UTC
-
Study explores if body weight changes how immunoglobulin works
Knowledge-focused Recruiting nowThis study looks at how body composition (like weight and muscle) affects the way immunoglobulin G (IgG) is processed in people with CIDP, a nerve disorder. Researchers will give IgG through a vein or under the skin and measure drug levels and half-life. The goal is to improve do…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated May 18, 2026 12:02 UTC